Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 131   

Articles published

JNJ 98.96 +0.21 (0.21%)
price chart
Johnson & Johnson Profit Jumps As Prescription Drug Sales Surge And Outlook ...
Johnson & Johnson, the maker of medicines like Tylenol and consumer products like Aveeno and Listerine, reported $18.1 billion in first quarter revenue, beating Street estimates of $17.99 billion and coming in 3.5% above the $17.5 billion reported for ...
Johnson & Johnson's Earnings Report Impresses  Motley Fool
Johnson & Johnson Reports 2014 First-Quarter Results:  Wall Street Journal
Related articles »  
Johnson & Johnson's Headache-Fixing Earnings, Mattel's Un-Fun Earnings, and ...
Sure, its business may not be as sexy as Google's, but Johnson & Johnson (NYSE: JNJ ) is our stock winner of the week after an earnings report that got rid of investors' headaches.
Sales of Johnson & Johnson's New Hepatitis C Drug Soar
Sales of Johnson & Johnson's New Hepatitis C Drug Soar. Olysio Sales Reach Higher-Than-Expected $354 Million in First Full Quarter on the Market.
Johnson & Johnson's Kim Kadlec Departs For AOL
Kim Kadlec, worldwide VP of the global marketing group at Johnson & Johnson Johnson & Johnson for the past eight years, is moving to AOL AOL to be head of relationship management, a new position.
Johnson & Johnson's Kim Kadlec Joining AOL  Adweek
AOL's Latest Executive Hiring: Johnson & Johnson's Kadlec  Wall Street Journal (blog)
Related articles »  
Why Johnson & Johnson's Patent Expiration Profile Is Fantastic
Very few firms have a more attractive investment profile than Johnson & Johnson. Johnson & Johnson boasts a cash-flow-derived Valuentum Dividend Cushion score of 2.2, and we don't see us removing it from the Dividend Growth portfolio anytime soon.
Why Coca-Cola and Johnson & Johnson Will Move the Dow Tomorrow
Johnson & Johnson has scheduled a conference call for 8:30 a.m. EDT following the release of its earnings report, which could come around 7:45 a.m.
Stocks to Watch: Coca-Cola, Johnson & Johnson, Zebra Technologies  Wall Street Journal (blog)
Jim Cramer: Why Johnson & Johnson (JNJ) and Coca-Cola (KO) Reported ...
Related articles »  
Johnson & Johnson Stock Attractive as It Raises Forecast
But Johnson & Johnson has delivered its share of winners that are fueling better-than-expected profit growth for the health-care giant.
Earnings Roundup: Johnson & Johnson Results Are Better Than They Appear  Motley Fool
Related articles »  
Johnson & Johnson Earnings: Will Tuesday Bring More Good News for J&J?
On Tuesday, Johnson & Johnson (NYSE: JNJ ) will release its quarterly report, and investors have to be pleased with the health-care conglomerate's ability to keep moving its earnings and revenue in the right direction.
How Big Is the Threat to This Johnson & Johnson Blockbuster?
Johnson & Johnson (NYSE: JNJ ) has been one of the most successful big drug companies over the past three years. Despite an industry-wide sales drag caused by patent expiration on top-selling drugs, Johnson has skirted the headwind thanks to a wave of ...
Motley Fool: Put Johnson & Johnson in long-term portfolio
Big blue-chip companies might not grow rapidly, but they can offer more stability than smaller counterparts, and they often pay dividends, too.
Johnson & Johnson's Earnings Made Easy  Motley Fool
Health of Johnson & Johnson  Worcester Telegram
Related articles »